R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Price:
1 259
ILS
1.53%
Market Cap:
₪149m
Relative Value
The Relative Value of one REKA stock under the Base Case scenario is 2 595.39 ILS. Compared to the current market price of 1 259 ILS, Rekah Pharmaceutical Industry Ltd is Undervalued by 51%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
REKA
Relative Value
Base Case
2 595.39
ILS
Undervaluation 51%
R
Multiples Across Competitors
REKA Competitors Multiples
Rekah Pharmaceutical Industry Ltd Competitors
Rekah Pharmaceutical Industry Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IL |
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
149m ILS | 0.5 | -10.6 | 10 | -66.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
960.1B USD | 14.7 | 46.5 | 31.4 | 33.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579.4B USD | 6.2 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
284.8B CHF | 4.6 | 30.3 | 12.8 | 14.9 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.1B GBP | 5.5 | 34.2 | 16.2 | 23.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
235.3B CHF | 5.4 | 21.6 | 13.3 | 17.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.4B USD | 4.5 | 16.2 | 10.1 | 11.8 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.4 | 13.3 | 9.8 | 11.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158B USD | 2.5 | 20.3 | 7.5 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.2B USD | 2.5 | 17.3 | 6.8 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
